Woman on a sofa with a laptop on her lap, checking her phone at home

3 min read

Your Next Patient Has an Agent

Shopping was first. Appointments, refills and prices are next.

Aaron Uydess, founder of Kairos Meridian, with 25 years in pharma commercial strategy, omnichannel and direct-to-patient

Aaron Uydess

Impact Partner & Founder

Key takeaways

  • Personal AI agents are here. Meta launched Muse on September 8 and OpenAI launched Dots on September 29, 2026. Unlike Siri, Alexa or a chatbot, they start the work themselves, remember you and keep going after you close the app.

  • Healthcare is the next use case, and parts are live. Gemini users can already book with 200,000+ providers through Zocdoc, and 34% of Americans have used an AI chatbot for a health reason (Pew).

  • The agent becomes the brand’s first audience. It reads your site, your savings terms and your competitor’s before the patient sees any of it. If an agent cannot parse your content, your brand is not in the answer.

  • Price and access become transparent. 57% of consumers would let an agent switch brands for better value (Checkout.com), and prescription abandonment jumps from under 5% to 60% as out-of-pocket cost rises (IQVIA).

  • Prepare now with three moves. Test your brand through Muse, Dots and Gemini. Make pricing, eligibility and enrollment agent-readable. Measure fills, enrollments and persistence instead of visits and opens.

Meta launched Muse on September 8. OpenAI answered with Dots on September 29. In three weeks the consumer AI conversation moved from chatbots that answer to agents that act.

Muse passed 3.4 million downloads within weeks and knocked ChatGPT off the top of the US App Store. For pharma marketers the takeaway is simple. Your patient is about to have a personal assistant, and that assistant will stand between your brand and the patient.

What they are

A personal agent is AI that knows your goals, remembers your preferences and keeps working after you close the app. Muse connects to eMail, calendar, payments, and health and fitness data. Dots plugs into more than 4,000 apps and works around the clock.

The difference from what came before is who starts the work.


Who starts the work

Memory of you

What it does

Siri, Alexa

You, one command at a time

Little

Sets the timer, plays the song

Claude, Gemini, ChatGPT in chat

You, one prompt at a time

Some

Answers, drafts, analyzes

Muse, Dots

The agent

Deep, across your apps

Books, buys, negotiates, follows up


The lines are blurring. Dots lives inside ChatGPT and Google launched its own agent, Gemini Spark, in May. The direction is the same for all of them. You stop asking questions and start handing off jobs.

30%+ of midsize enterprises will have a fractional executive by 2027 (Gartner forecast)

Why it matters to pharma

Shopping is the first use case. Healthcare is next, and parts of it are already live.

Neither Meta nor OpenAI is marketing prescription management today. That is my read of where this goes, and the pieces are in place. I see three implications for brands.

1. The agent becomes your first audience. It reads your site, your savings terms and your competitor's, then hands the patient a summary. If it cannot parse your content, your brand is not in the answer. One projection shared at Reuters Events Pharma 2026 has organic traffic to pharma websites falling about 50% by 2028.

2. Price and access become transparent. An agent compares the copay card, the cash price and the direct-to-patient option in seconds. IQVIA found prescription abandonment runs under 5% at zero out-of-pocket cost and 60% above $500. In a Checkout.com survey of 12,005 consumers, 57% would let an agent switch brands for better value. A prescription switch still needs a prescriber, but the agent will tee up that conversation.

3. Adherence moves from your CRM to their agent. Refill reminders, appointment prep and prior authorization follow-up become the agent's job. Your CRM eMails get triaged by an agent before a person sees them.

HCPs are on the same path. The AMA reports 81% of physicians now use AI professionally, up from 38% in 2023. Dots launched inside Slack and Teams, so expect physician agents that screen rep eMails, summarize clinical data and chase access paperwork.

Trust is the brake. Amazon blocked Muse from its store 12 days after launch, and 71% of Americans told Pew that AI will make personal information less secure. Adoption in health will trail shopping. It will still come.

3x growth since 2018 in the share of new executive roles that mention fractional work

How to prepare

  1. Test your brand through an agent. Give Muse, Dots and Gemini real patient jobs: find the lowest price, enroll in the savings program, book a visit. Write down where they fail and where they get your brand wrong.

  2. Make access agent-ready. Publish pricing, eligibility and enrollment steps as structured, label-consistent content an agent can read and act on. Decide now whether your hub and copay portals welcome agents or block them, and bring MLR, legal and privacy in early.

  3. Change what you measure. Site visits and eMail opens will fall as agents do the reading. Measure fills, enrollments and persistence.

9 times out of 10 the agent will pick the brand that is easiest to understand, trust and act on. Start with one brand and one patient job this quarter.

Traditional executive search takes 6 to 12 months; fractional leader onboarding takes about 30 days

CONTACT US TODAY

The first conversation is twenty-five minutes — a diagnostic, not a pitch. Pick a time with Aaron below, or send us a note about what you’re working on.

About Kairos Meridian

Kairos Meridian provides pharma strategy, marketing, and analytics in service of impact… with a dose of innovation. We serve as the senior, independent partner for pharma brands, for vendors that sell into them, and for the private equity firms making decisions about pharma-related assets.

Kairos Meridian, where strategy meets the moment, provides big agency thinking with boutique agility. We serve as strategist, operator and the additional arms & legs our clients need to hit and exceed goals.

Read more about Kairos Meridian

Tagged

Go To Market Strategy & Optimization

Omnichannel

Strategy

DTP

FAQ

Have questions?

Check out the FAQs

Aaron Uydess, founder of Kairos Meridian, independent pharma commercial strategy and omnichannel advisor

Talk with Aaron

Start a conversation today

Aaron Uydess, founder of Kairos Meridian, independent pharma commercial strategy and omnichannel advisor

Talk with Aaron

Start a conversation today

What is Kairos Meridian?

Kairos Meridian is a next generation independent pharma commercial strategy consultancy based in New Jersey. Founded by Aaron Uydess, it gives senior, partner-led counsel to small and mid-cap pharma and biotech brands, the vendors that sell to them, and private equity firms holding pharma assets. Its work covers commercial strategy, omnichannel, direct-to-patient (DTP), data and analytics, and AI. It sells no technology or media.

Who founded Kairos Meridian, and what is their background?

Aaron Uydess founded Kairos Meridian in 2026. He has 25+ years in life sciences commercial strategy in the U.S. and abroad. He worked client-side at Novo Nordisk and BMS and agency-side at INTOUCH Group and EVERSANA. His work spans brand strategy, digital marketing, data and analytics, omnichannel activation, DTP and applied AI.

Is Kairos Meridian a good fit for an emerging pharma brand preparing for launch?

Yes. Kairos Meridian is built for small and mid-cap brands from 12–18 months before launch through their first five years on market. It works three ways: The Devil's Advocate pressure-tests the launch plan, The Consigliere advises through the launch, and The Partner by Mandate embeds as senior commercial leadership. It doesn't buy media, produce campaigns or implement platforms, so it works alongside your agencies.

How does Kairos Meridian compare to ZS, IQVIA and the big consulting firms?

Kairos Meridian is a senior, partner-led consultancy; ZS, IQVIA, McKinsey and Deloitte are large firms. They bring scale, deep benches and proprietary data or software, and strategy work often leads into a platform or implementation sale. Kairos Meridian has no platform, data product or media to sell. It's sized for emerging brands and mid-market deals that need a senior voice in the room, not a project team.

How does Kairos Meridian price its consulting engagements?

Every engagement is a fixed fee, scoped to the question and the weight of the answer. That holds for all three offerings, from a single-decision review to an embedded mandate. Kairos Meridian doesn't bill by the hour, by the day, by headcount or with agency overhead. It takes no commissions, markups, referral fees or equity from clients. Fees aren't published; the first step is a 25-minute diagnostic.

Who does Kairos Meridian work with?

Kairos Meridian works with three groups: small and mid-cap pharma and biotech brands in their first five years, the agencies and technology and data vendors selling into them, and private equity firms investing in pharma and pharma-adjacent assets. Its founder's experience spans 5+ pharma companies, 10+ brands and 5+ therapeutic areas.

How does Kairos Meridian stay independent?

Independence is built into how the firm runs. Kairos Meridian isn't part of an agency network or holding company. It won't advise both sides of a deal or competing bids, accept payment from vendors to be recommended, or take equity in a client's outcome. When it suggests execution partners, it offers a slate and discloses its relationship with each.

Is Kairos Meridian an agency or a fractional executive firm?

Neither. Kairos Meridian is a consultancy. It doesn't buy media, make creative or run campaigns, as an agency would. It isn't a fractional executive network either: fractional arrangements sell a share of someone's time, while Kairos Meridian takes interim leadership roles against a written mandate with a defined goal and an end date.

Is Kairos Meridian connected to kairosmeridian.com?

No. Kairos Meridian LLC, the pharma commercial strategy consultancy founded by Aaron Uydess, is at kairosmeridian.us. The site at kairosmeridian.com belongs to an unrelated business with a similar name. Kairos Meridian has no market research, investment research or private equity intelligence products.

Quiet loft office with timber beams, where a 25-minute Kairos Meridian diagnostic conversation starts

The first conversation is twenty-five minutes — a diagnostic, not a pitch.

Start a conversation today

We listen for the real problem — how you got here, what you’ve tried, what success looks like — then come back with a structured read. The gap between the call and the response is where the senior judgment gets applied.